IntelliPharmaCeutics International Inc. (IPCI:TSX) Investor Relations Material

Overview

Toronto-based Intellipharmaceutics is a pioneering company in the global pharmaceutical industry, having been established in 1998. A key aspect of Intellipharmaceutics' offerings is its proprietary Hypermatrix™ technology, which serves as a versatile and proven multidimensional controlled-release drug delivery platform. This innovation supports the development of a wide variety of pharmaceutical products, including those already on the market as well as new drug types. Intellipharmaceutics' pipeline comprises generic and new drugs spanning multiple therapeutic categories.

Frequently Asked Questions

What is IntelliPharmaCeutics International Inc.'s ticker?

IntelliPharmaCeutics International Inc.'s ticker is IPCI

What exchange is IntelliPharmaCeutics International Inc. traded on?

The company's shares trade on the TSX stock exchange

Where are IntelliPharmaCeutics International Inc.'s headquarters?

They are based in Etobicoke, Toronto

How many employees does IntelliPharmaCeutics International Inc. have?

There are 51-200 employees working at IntelliPharmaCeutics International Inc.

What is IntelliPharmaCeutics International Inc.'s website?

It is https://www.intellipharmaceutics.com/

What type of sector is IntelliPharmaCeutics International Inc.?

IntelliPharmaCeutics International Inc. is in the Healthcare sector

What type of industry is IntelliPharmaCeutics International Inc.?

IntelliPharmaCeutics International Inc. is in the Biotechnology industry

Who are IntelliPharmaCeutics International Inc.'s peers and competitors?

The following five companies are IntelliPharmaCeutics International Inc.'s industry peers:

- Recce Pharmaceuticals

- PhaseBio Pharmaceuticals, Inc.

- Intelgenx Technologies Corp

- Invex Therapeutics Ltd

- ChromaDex